OBJECTIVE： To evaluate the affordability of 3 anti-tumor targeted drugs gefitinib， trastuzumab and sunitinib in urban and rural residents of Hubei province， and to provide reference for medical insurance price admission of anti-malignant tumor targeted drugs in China. METHODS： Referring to the incidence of malignant tumor stated in statistical yearbook of Hubei province and income data of urban and rural residents in Hubei province， based on the policy of reducing the price of imported drugs by 50％ mentioned in the national drug price negotiations， and assume the drugs are included in the medical insurance reimbursement list， WHO/HAI standard survey method， catastrophic expenditure evaluation method and poverty effect evaluation method were adopted to calculate the affordability of 3 drugs. RESULTS： According to WHO/HAI standard survey method， increment of payment for 3 drugs were 64.00％-74.00％ before and after 50％ discount and reimbursement. According to catastrophic expenditure evaluation method， 50％ discount of gefitinib and reimbursement gefitinib， trastuzumab and sunitinib in urban area would result in catastrophic expenditures of 20.00％、59.28％ and 35.48％ patients； in rural area， would result in catastrophic expenditures of 50.63％、74.72％ and 75.93％ patients. According to poverty effect evaluation method， 50％ discount of 3 drugs and reimbursement caused less than 31.95％ urban and rural patients falling to poverty. CONCLUSIONS： Fifty percentage discount of 3 anti-tumor targeted drugs mentioned in the national drug price negotiations cause the economic burden more serious for rural residents than urban residents. In the formulation of policies， the corresponding reimbursement ratio should be adjusted according to urban and rural areas， drug price and disease types for a balance of patients with different economic burden.